|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
2.
|
Di Cosimo S and Baselga J: Management
breast cancer with targeted agents: importance of heterogeneity.
Nat Rev Clin Oncol. 7:139–147. 2010.PubMed/NCBI
|
|
3.
|
Rahman M, Pumphrey JG and Lipkowitz S: The
TRAIL to targeted therapy of breast cancer. Adv Cancer Res.
103:43–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Smith I, Procter M, Gelber RD, Guillaume
S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G,
Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R,
Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N,
Wist E, Sánchez Rovira P and Piccart-Gebhart MJ: HERA study team:
2-year follow-up of trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer: a randomised controlled trial. Lancet.
369:29–36. 2007.
|
|
5.
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG,
Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas
EP, Lingle WL, Klein PM, Ingle JN and Wolmark N: Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast cancer. N
Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Joensuu H, Kellokumpu-Lehtinen PL, Bono P,
Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A,
Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L,
Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M,
Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I and Isola J; for
the FinHer Study Investigators: Adjuvant docetaxel or vinorelbine
with or without trastuzumab for breast cancer. N Engl J Med.
354:809–820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to
neoadjuvant therapy and long-term survival in patients with
triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Petricoin EF III, Hackett JL, Lesko LJ,
Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC
and Sistare FD: Medical applications of microarray technologies: a
regulatory science perspective. Nat Genet. 32:474–479. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Huang DW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
Bioinformatics Resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
11.
|
Huang DW, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ,
Liu C, Li JL, Ding YQ and Li JM: A five-gene signature as a
potential predictor of metastasis and survival in colorectal
cancer. J Pathol. 220:475–489. 2010.PubMed/NCBI
|
|
13.
|
Ueki T, Park JH, Nishidate T, Kijima K,
Hirata K, Nakamura Y and Katagiri T: Ubiquitination and
downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T
overexpression in human breast cancer cells. Cancer Res.
69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Loussouarn D, Campion L, Leclair F,
Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R and
Jézéquel P: Validation of UBE2C protein as a prognostic marker in
node-positive breast cancer. Br J Cancer. 101:166–173. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Arumugam T and Logsdon CD: S100P: a novel
therapeutic target for cancer. Amino Acids. 41:893–899. 2011.
View Article : Google Scholar
|
|
16.
|
Xiang T, Li L, Yin X, Yuan C, Tan C, Su X,
Xiong L, Putti TC, Oberst M, Kelly K, Ren G and Tao Q: The
ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and
apoptosis through stabilizing p53 and is frequently silenced in
breast cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yoon CH, Kim MJ, Lee H, Kim RK, Lim EJ,
Yoo KC, Lee GH, Cui YH, Oh YS, Gye MC, Lee YY, Park IC, An S, Hwang
SG, Park MJ, Suh Y and Lee SJ: PTTG1 oncogene promotes tumor
malignancy via epithelial to mesenchymal transition and expansion
of cancer stem cell population. J Biol Chem. 287:19516–19527. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Jin W, Liu Y, Xu SG, Yin WJ, Li JJ, Yang
JM and Shao ZM: UHRF1 inhibits MDR1 gene transcription and
sensitizes breast cancer cells to anticancer drugs. Breast Cancer
Res Treat. 124:39–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ford HL, Landesman-Bollag E, Dacwag CS,
Stukenberg PT, Pardee AB and Seldin DC: Cell cycle-regulated
phosphorylation of the human SIX1 homeodomain protein. J Biol Chem.
275:22245–22254. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Shimo A, Nishidate T, Ohta T, Fukuda M,
Nakamura Y and Katagiri T: Elevated expression of protein regulator
of cytokinesis 1, involved in the growth of breast cancer cells.
Cancer Sci. 98:174–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Di Leo A and Isola J: Topoisomerase II
alpha as a marker predicting the efficacy of anthracyclines in
breast cancer: are we at the end of the beginning? Clin Breast
Cancer. 4:179–186. 2003.PubMed/NCBI
|
|
22.
|
Nakagawa M, Bando Y, Nagao T, Morimoto M,
Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M
and Tangoku A: Expression of p53, Ki-67, E-cadherin, N-cadherin and
TOP2A in triple-negative breast cancer. Anticancer Res.
31:2389–2393. 2011.PubMed/NCBI
|
|
23.
|
Adélaïde J, Finetti P, Bekhouche I,
Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N,
Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J,
Birnbaum D, Bertucci F and Chaffanet M: Integrated profiling of
basal and luminal breast cancers. Cancer Res. 67:11565–11575.
2007.PubMed/NCBI
|
|
24.
|
Liu RZ, Graham K, Glubrecht DD, Germain
DR, Mackey JR and Godbout R: Association of FABP5 expression with
poor survival in triple-negative breast cancer: implication for
retinoic acid therapy. Am J Pathol. 178:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kalashnikova EV, Revenko AS, Gemo AT,
Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW:
ANCCA/ATAD2 overexpression identifies breast cancer patients with
poor prognosis, acting to drive proliferation and survival of
triple-negative cells through control of B-Myb and EZH2. Cancer
Res. 70:9402–9412. 2010. View Article : Google Scholar
|
|
26.
|
Parris TZ, Danielsson A, Nemes S, Kovács
A, Delle U, Fallenius G, Möllerström E, Karlsson P and Helou K:
Clinical implications of gene dosage and gene expression patterns
in diploid breast carcinoma. Clin Cancer Res. 16:3860–3874. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ai L, Tao Q, Zhong S, Fields CR, Kim WJ,
Lee MW, Cui Y, Brown KD and Robertson KD: Inactivation of Wnt
inhibitory factor-1 (WIF1) expression by epigenetic silencing is a
common event in breast cancer. Carcinogenesis. 27:1341–1348. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh
MC, Chen CL and Yang RB: SCUBE2 suppresses breast tumor cell
proliferation and confers a favorable prognosis in invasive breast
cancer. Cancer Res. 69:3634–3641. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Tsunoda N, Kokuryo T, Oda K, Senga T,
Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as a novel
molecular target for the treatment of breast carcinoma. Cancer Sci.
100:111–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Suzuki K, Kokuryo T, Senga T, Yokoyama Y,
Nagino M and Hamaguchi M: Novel combination treatment for
colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci.
101:1163–1169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Ueki T, Nishidate T, Park JH, Lin ML,
Shimo A, Hirata K, Nakamura Y and Katagiri T: Involvement of
elevated expression of multiple cell-cycle regulator, DTL/RAMP
(denticleless/RA-regulated nuclear matrix associated protein), in
the growth of breast cancer cells. Oncogene. 27:5672–5683. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lin ML, Park JH, Nishidate T, Nakamura Y
and Katagiri T: Involvement of maternal embryonic leucine zipper
kinase (MELK) in mammary carcinogenesis through interaction with
Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer
Res. 9:R172007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Shimo A, Tanikawa C, Nishidate T, Lin ML,
Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M, Nakamura Y
and Katagiri T: Involvement of kinesin family member 2C/mitotic
centromere-associated kinesin overexpression in mammary
carcinogenesis. Cancer Sci. 99:62–70. 2008.PubMed/NCBI
|
|
35.
|
Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao
Q, Hyytiainen M, Keski-Oja J, Law S, Srivastava G, Tang J, Tsao SW,
Chen H, Stanbridge EJ and Lung ML: The ECM protein LTBP-2 is a
suppressor of esophageal squamous cell carcinoma tumor formation
but higher tumor expression associates with poor patient outcome.
Int J Cancer. 129:565–573. 2011. View Article : Google Scholar
|
|
36.
|
Sathyanarayana UG, Maruyama R, Padar A,
Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman
HB, Czerniak B and Gazdar AF: Molecular detection of noninvasive
and invasive bladder tumor tissues and exfoliated cells by aberrant
promoter methylation of laminin-5 encoding genes. Cancer Res.
64:1425–1430. 2004. View Article : Google Scholar
|
|
37.
|
Senchenko VN, Krasnov GS, Dmitriev AA,
Kudryavtseva AV, Anedchenko EA, Braga EA, Pronina IV, Kondratieva
TT, Ivanov SV, Zabarovsky ER and Lerman MI: Differential expression
of CHL1 gene during development of major human cancers. PLoS One.
6:e156122011. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
do Carmo Avides M and Glover DM: Abnormal
spindle protein, Asp, and the integrity of mitotic centrosomal
microtubule organizing centers. Science. 283:1733–1735.
1999.PubMed/NCBI
|
|
39.
|
Cheeseman IM, Hori T, Fukagawa T and Desai
A: KNL1 and the CENP-H/I/K complex coordinately direct kinetochore
assembly in vertebrates. Mol Biol Cell. 19:587–594. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Hayward DG and Fry AM: Nek2 kinase in
chromosome instability and cancer. Cancer Lett. 237:155–166. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Nakano I, Masterman-Smith M, Saigusa K,
Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R,
Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM,
Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS,
Terskikh AV and Kornblum HI: Maternal embryonic leucine zipper
kinase is a key regulator of the proliferation of malignant brain
tumors, including brain tumor stem cells. J Neurosci Res. 86:48–60.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Jeong H, Ryu YJ, An J, Lee Y and Kim A:
Epithelial-mesenchymal transition in breast cancer correlates with
high histological grade and triple-negative phenotype.
Histopathology. 60:E87–E95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Horvath S, Zhang B, Carlson M, Lu KV, Zhu
S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck
AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy
TF, Nelson SF and Mischel PS: Analysis of oncogenic signaling
networks in glioblastoma identifies ASPM as a molecular target.
Proc Natl Acad Sci USA. 103:17402–17407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Moroi Y, Peebles C, Fritzler MJ,
Steigerwald J and Tan EM: Autoantibody to centromere (kinetochore)
in scleroderma sera. Proc Natl Acad Sci USA. 77:1627–1631. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Tomonaga T, Matsushita K, Yamaguchi S,
Oohashi T, Shimada H, Ochiai T, Yoda K and Nomura F: Overexpression
and mistargeting of centromere protein-A in human primary
colorectal cancer. Cancer Res. 63:3511–3516. 2003.PubMed/NCBI
|
|
46.
|
de la Guardia C, Casiano CA,
Trinidad-Pinedo J and Báez A: CENP-F gene amplification and
overexpression in head and neck squamous cell carcinomas. Head
Neck. 23:104–112. 2001.PubMed/NCBI
|
|
47.
|
Grützmann R, Pilarsky C, Ammerpohl O,
Lüttges J, Böhme A, Sipos B, Foerder M, Alldinger I, Jahnke B,
Schackert HK, Kalthoff H, Kremer B, Klöppel G and Saeger HD: Gene
expression profiling of microdissected pancreatic ductal carcinomas
using high-density DNA microarrays. Neoplasia. 6:611–622.
2004.PubMed/NCBI
|
|
48.
|
Bièche I, Vacher S, Lallemand F,
Tozlu-Kara S, Bennani H, Beuzelin M, Driouch K, Rouleau E,
Lerebours F, Ripoche H, Cizeron-Clairac G, Spyratos F and Lidereau
R: Expression analysis of mitotic spindle checkpoint genes in
breast carcinoma: role of NDC80/HEC1 in early breast
tumorigenicity, and a two-gene signature for aneuploidy. Mol
Cancer. 10:232011.PubMed/NCBI
|
|
49.
|
Hu Z, Huang G, Sadanandam A, Gu S, Lenburg
ME, Pai M, Bayani N, Blakely EA, Gray JW and Mao JH: The expression
level of HJURP has an independent prognostic impact and predicts
the sensitivity to radiotherapy in breast cancer. Breast Cancer
Res. 12:R182010. View Article : Google Scholar : PubMed/NCBI
|
